Corneal Reinnervation after Recombinant Form of Nerve Growth Factor Treatment in Patients with Neurotrophic Keratitis
Open Access
- 24 December 2024
- journal article
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 21 (4) , 786-792
Abstract
Purpose. To evaluate corneal reinnervation in patients with neurotrophic keratitis after treatment with a recombinant form of human nerve growth factor (cenegermin) using confocal microscopy.Patients and methods. The results of 4 patients treatment with neurotrophic keratitis of various etiology were analyzed. All patients showed ineffectiveness of reparative and etiotropic therapy for 3 months, therefore, cenegermin was prescribed as pathogenetic treatment. Patients underwent standard and specialised diagnostics. In addition, confocal microscopy of the cornea was performed with subsequent analysis of the density of the subbasal nerve plexus, maximum, minimum and total lengths of the corneal nerves using the ImageJ program. The maximum follow-up period was 12 months.Results. After 8 weeks of treatment, complete epithelialisation and an increase in corneal sensitivity were observed in all patients. Analysis of the confocal scans showed that the maximum density of the subbasal nerve plexus was observed after 8 weeks of treatment. With increasing follow-up, the density of the subbasal nerve plexus increased to a lesser extent and the length of the nerves increased to a greater extent.Conclusion. Treatment with a recombinant form of human nerve growth factor for 8 weeks results in regeneration and significant increase of the subbasal nerve plexus density. With the increase of follow-up period corneal reinnervation continues due to elongation of nerve fibers.Keywords
This publication has 28 references indexed in Scilit:
- Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)Ophthalmology and Therapy, 2024
- Characteristics of the ocular surface in neurotrophic keratitis induced by trigeminal nerve injury following neurosurgeryInternational Ophthalmology, 2022
- Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatmentAmerican Journal of Ophthalmology Case Reports, 2022
- Neurotrophic keratopathy: Clinical presentation and effects of cenegerminAmerican Journal of Ophthalmology Case Reports, 2022
- Incidence, prevalence, and outcome of moderate to severe neurotrophic keratopathy in a German tertiary referral center from 2013 to 2017Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
- Direct Versus Indirect Corneal Neurotization for the Treatment of Neurotrophic KeratopathyAmerican Journal of Ophthalmology, 2020
- Neurotrophic keratopathy and diabetes mellitusEye, 2005
- Neurotrophic keratitisEye, 2003
- Corneal nerves: structure, contents and functionExperimental Eye Research, 2003
- Stimulation of epithelial cell growth by the neuropeptide substance PJournal of Cellular Biochemistry, 1993